Diet Impacts on Gene Expression in Healthy Colon Tissue: Insights from the BarcUVa-Seq Study.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
16 Sep 2024
Historique:
received: 14 08 2024
revised: 06 09 2024
accepted: 14 09 2024
medline: 29 9 2024
pubmed: 28 9 2024
entrez: 28 9 2024
Statut: epublish

Résumé

(1) Introduction: The global rise of gastrointestinal diseases, including colorectal cancer and inflammatory bowel diseases, highlights the need to understand their causes. Diet is a common risk factor and a crucial regulator of gene expression, with alterations observed in both conditions. This study aims to elucidate the specific biological mechanisms through which diet influences the risk of bowel diseases. (2) Methods: We analyzed data from 436 participants from the BarcUVa-Seq population-based cross-sectional study utilizing gene expression profiles (RNA-Seq) from frozen colonic mucosal biopsies and dietary information from a semi-quantitative food frequency questionnaire. Dietary variables were evaluated based on two dietary patterns and as individual variables. Differential expression gene (DEG) analysis was performed for each dietary factor using edgeR. Protein-protein interaction (PPI) analysis was conducted with STRINGdb v11 for food groups with more than 10 statistically significant DEGs, followed by Reactome-based enrichment analysis for the resulting networks. (3) Results: Our findings reveal that food intake, specifically the consumption of blue fish, alcohol, and potatoes, significantly influences gene expression in the colon of individuals without tumor pathology, particularly in pathways related to DNA repair, immune system function, and protein glycosylation. (4) Discussion: These results demonstrate how these dietary components may influence human metabolic processes and affect the risk of bowel diseases.

Identifiants

pubmed: 39339731
pii: nu16183131
doi: 10.3390/nu16183131
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Asociación Española Contra el Cáncer
ID : GCTRA18022MORE
Organisme : DISCERN HORIZON-MISS-2021-CANCER-02-03
ID : 101096888
Organisme : Instituto de Salud Carlos III
ID : FORT23/00032; PI17-00092 and PI20-01439
Organisme : NIH HHS
ID : R01CA273198; R01 CA204279; R01 CA143237 and R01 CA201407
Pays : United States

Auteurs

Mireia Obón-Santacana (M)

Unit of Biomarkers and Susceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), 08908 L'Hospitalet del Llobregat, Barcelona, Spain.
ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.

Ferran Moratalla-Navarro (F)

Unit of Biomarkers and Susceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), 08908 L'Hospitalet del Llobregat, Barcelona, Spain.
ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.

Elisabet Guinó (E)

Unit of Biomarkers and Susceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), 08908 L'Hospitalet del Llobregat, Barcelona, Spain.
ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.

Robert Carreras-Torres (R)

Digestive Diseases and Microbiota Group, Department of Gastroenterology, Girona Biomedical Research Institute (IDIBGI), Hospital Universitari de Girona Dr. Josep Trueta, 17190 Salt, Girona, Spain.

Virginia Díez-Obrero (V)

Unit of Biomarkers and Susceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), 08908 L'Hospitalet del Llobregat, Barcelona, Spain.
ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.

David Bars-Cortina (D)

Unit of Biomarkers and Susceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), 08908 L'Hospitalet del Llobregat, Barcelona, Spain.
ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Barcelona, Spain.

Gemma Ibáñez-Sanz (G)

ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
Gastroenterology Department, Bellvitge University Hospital, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.

Lorena Rodríguez-Alonso (L)

Gastroenterology Department, Bellvitge University Hospital, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.

Alfredo Mata (A)

Digestive System Service, Moisés Broggi Hospital, 08970 Sant Joan Despí, Spain.

Ana García-Rodríguez (A)

Endoscopy Unit, Digestive System Service, Viladecans Hospital-IDIBELL, 08840 Viladecans, Barcelona, Spain.

Matthew Devall (M)

Department of Family Medicine, University of Virginia, Charlottesville, VA 22903, USA.

Graham Casey (G)

Department of Genome Sciences, University of Virginia, Charlottesville, VA 22903, USA.

Li Li (L)

Department of Family Medicine, University of Virginia, Charlottesville, VA 22903, USA.

Victor Moreno (V)

Unit of Biomarkers and Susceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), 08908 L'Hospitalet del Llobregat, Barcelona, Spain.
ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH